Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Curaleaf Holdings Inc T.CURA

Alternate Symbol(s):  CURLF

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including... see more

TSX:CURA - Post Discussion

Curaleaf Holdings Inc > FDA gives green light to PTSD marijuana study
View:
Post by blackspade799 on Nov 27, 2024 9:45am

FDA gives green light to PTSD marijuana study

The Food and Drug Administration (FDA) this week authorized a long-delayed clinical trial to test whether smoking marijuana can be used to treat post-traumatic stress disorder (PTSD) in veterans.

The trial, sponsored by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS), has been blocked by the FDA since 2021. The agency had raised a variety of objections, including that allowing people to inhale high-potency cannabis was dangerous to their health.

The FDA also objected to the study’s “self-titration” dosing method, which will allow participants to smoke as much cannabis as they feel they need to relieve their symptoms up to a daily limit.

But on Wednesday, MAPS announced that the FDA will allow the trial to proceed. Importantly, they said the FDA no longer objects to either smoking or letting participants choose their preferred amount.

https://www.aol.com/fda-gives-green-light-ptsd-231111607.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities